PR Newswire (Feb 8, 2013)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
486 people get YMI articles and Market Currents by email alert.
Get email alerts on YMI »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
PR Newswire (Feb 7, 2013)
-
-
PR Newswire (Jan 31, 2013)
-
-
-
-
PR Newswire (Dec 21, 2012)
-
-
A Not-So-Bad Acquisition By GileadHenry Kawabe • Fri, Dec 14, 2012 -
-
-
Stock Watch Wednesday, 12 DecemberVFC's Stock House • Wed, Dec 12, 2012 -
PR Newswire (Dec 12, 2012)
-
PR Newswire (Dec 9, 2012)
-
PR Newswire (Dec 3, 2012)
-
PR Newswire (Nov 20, 2012)
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
-
YM BioSciences: YMI Trading Below Cash?Mike Havrilla • Fri, Dec 14, 2007
-
Versant: YM Biosciences Now a 'Speculative Buy'FP Trading Desk • Tue, Apr 10, 2007
-
-
-
-
-
-
A Not-So-Bad Acquisition By GileadHenry Kawabe • Fri, Dec 14, 2012
-
-
Stock Watch Wednesday, 12 DecemberVFC's Stock House • Wed, Dec 12, 2012
-
-
-
-
-
-
-
-
-
-
-
-
There are no Transcripts on YMI.
-
PR Newswire (Feb 8, 2013)
-
PR Newswire (Feb 7, 2013)
-
PR Newswire (Jan 31, 2013)
-
PR Newswire (Dec 21, 2012)
-
PR Newswire (Dec 12, 2012)
-
PR Newswire (Dec 9, 2012)
-
PR Newswire (Dec 3, 2012)
-
PR Newswire (Nov 20, 2012)
-
PR Newswire (Nov 9, 2012)
-
PR Newswire (Oct 11, 2012)
-
PR Newswire (Sep 21, 2012)
-
PR Newswire (May 11, 2012)
-
PR Newswire (Dec 12, 2011)
-
at CNBC.com (Apr 21, 2011)
-
at MarketWatch.com (Oct 19, 2010)
YMI vs. ETF Alternatives
Company Description
Currently, there's no company description for YMI.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, February 7, 9:26 AM YM BioSciences (YMI): FQ2 EPS of -$0.07 misses by $0.01. Revenue of $3.86M beats by $2.3M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Friday, January 18, 3:43 PM YM BioSciences (YMI) says its buyout by a wholly owned subsidiary of Gilead Sciences (GILD +0.8%) has been endorsed by proxy advisory firms Institutional Investor Services and Glass, Lewis & Co. ISI says the all-cash deal offers a satisfactory premium, while Glass Lewis also notes that the YMI board of directors conducted a reasonable review of strategic alternatives available to the company prior to entering into the proposed agreement. Comment! [Healthcare, M&A]
-
Wednesday, December 12, 2012, 12:45 PM
Midday top 10 gainers: YMI +77%. DSTI +73%. TELK +25%. LDK +21%. JKS +23%. JASO +21%. TSL +20%. YGE +19%. CBMX +14%. SOL +17%.
Midday top 10 Losers: RSOL -14%. CENT -13%. ACUR -11%. TAS -11%. CATO -10%. CRWS -9%. AVD -9%. CRL -8%. AXK -8%. LTBR -8%. Comment! [On the Move] - Wednesday, December 12, 2012, 9:46 AM Gilead Sciences (GILD +0.4%) agrees to acquire YM BioSciences (YMI) for $510M, with the $2.95/share offer representing an 81% premium to the latter's close of $1.63 yesterday. With the deal, Gilead will gain access to YM's blood and immune cell disorder drugs. Its lead drug candidate is CYT387 for treating myelofibrosis, a progressive, chronic bone marrow disease. YM shares sky 78%. (PR) Comment! [Healthcare, On the Move, M&A]
-
Wednesday, December 12, 2012, 9:10 AM
Premarket gainers: YMI +79%. DSTI +15%. SCMP +11%. ACAD +9%. BGMD +10%.
Losers: RSOL -16%. CIE -11%. MCP -6%. Comment! [On the Move] - Wednesday, February 22, 2012, 10:28 AM YM Biosciences (YMI +6.3%) gets a boost from postitive comments out of Wells Fargo this morning, saying that recent weakness has created a buying a opportunity in the stock. Wells believes investors are failing to recognize the potential of the company's lead drug as both a treatment for myelofibrosis as well as other applications. Comment! [Healthcare, On the Move, Quick Ideas]
- Tuesday, December 13, 2011, 1:32 PM Shares of YM Biosciences (YMI +16.1%) fall back to earth a bit after surging over 20% in AH and premarket trading on positive results on testing of its CYT387 drug. Rodman & Renshaw's Reni Benjamin says the big takeaway from the data is that it meets the threshold of attracting interest from other companies looking to partner. Comment! [On the Move, Healthcare, Quick Ideas]
-
Tuesday, December 13, 2011, 9:05 AM
Premarket gainers: SYNO +51%. YMI +23%. URBN +12%. AMR +12%. MBI +9%. MS 9+5 ARNA +5%. AINV +4%. DMND +3%. CLWR +3%. AEZS +3%. DRYS +3%.
Losers: IVN -15%. BBY -8%. PSE -5%. IRE -3%. Comment! [On the Move] - Monday, December 12, 2011, 5:27 PM YM BioSciences (YMI) surges 21.9% AH after reporting positive results for the Phase I/II study of its CYT387 drug for treating myleofibrosis, both with regards to efficacy and safety. The company hopes to start "pivotal trials" for the drug in mid-2012. Comment! [Healthcare, On the Move]
-
Thursday, July 7, 2011, 9:05 AM
Premarket gainers: APAC +56%. MCZ +14%. OCZ +9%. RENN +8%. PMI +7%. TGT +6%. REDF +5%. DANG +5%. KSS +5%. MOBI +5%. STX +4%. BPAX +4%. GPL +4%. LTD +4%. ASML +4%. YOKU +3%. M +3%. STD +3%. SODA +3%. SINA +3%. NOK +3%. RDN +3%.
Losers: AFFX -16%. LL -16%. FST -7%. YMI -6%. JCP -4%. AIB -3%. Comment! [On the Move] -
Tuesday, December 14, 2010, 9:00 AM
Premarket gainers: GXDX +17%. AMGN +4%. BP +4%.
Losers: LCI -13%. BBY -13%. LPH -12%. ICO -11%. LXRX -10%. YMI -8%. AHT -6%. OXPS -5%. VECO -5%. REE -5%. WPZ -4%. Comment! -
Monday, April 19, 2010, 9:00 AM
Premarket gainers: CRN +35%. YMI +9%. CTIC +5%. IMMU +4%. SQNM +4%.
Losers: RNN -13%. TSFG -7%. SPF -7%. PALM -6%. FRE -5%. FNM -5%. Comment! -
Thursday, September 17, 2009, 9:00 AM
Premarket gainers: AMR +20%. YMI +19%. BBI +8%. PIR +7%. RZ +5%. DFS +4%. LCC +4%. MGM +4%. CVM +4%.
Losers: SNV -7%. EXK -6%. AIB -4%. Comment!
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.